Boehringer Ingelheim has emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF). COPD is a serious, progressive lung disease that limits airflow in the lungs. COPD is preventable and treatable but not curable and by 2033 it is predicted to be the third leading cause of death worldwide.1 An important goal in the management of COPD is increaseing a patient's ability to live their life to the extent they love to and keep active for longer.

1What is chronic obstructive pulmonary disease (COPD)? World Health Organisation.2013. (accessed August 2018)

Explore Our Products


Spiolto® Respimat®

SPIOLTO® RESPIMAT® is a once daily long-acting LAMA/LABA therapy of tiotropium 5 mcg (LAMA) and olodaterol 5 mcg (LABA), delivered via RESPIMAT®. It is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). SPIOLTO® RESPIMAT® is administered as 2 puffs, once daily.1


1. SPIOLTO® Prescribing Information

Learn more

Related content

Production date: Jan 2019